Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Status:
RECRUITING
Trial end date:
2027-09-10
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses. It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of CC312 in adult patients with moderate to severe systemic lupus erythematosus (SLE).